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The myelin sheaths wrapped around axons by oligodendrocytes are crucial for brain 
function. In ischaemia myelin is damaged in a Ca2+-dependent manner, abolishing 
action potential propagation1,2. This has been attributed to glutamate release activating 
Ca2+-permeable NMDA receptors2-4. Surprisingly, we now show that NMDA does not 
raise [Ca2+]i in mature oligodendrocytes and that, although ischaemia evokes a 
glutamate-triggered membrane current4, this is generated by a rise of extracellular [K+] 
and decrease of membrane K+ conductance. Nevertheless, ischaemia raises 
oligodendrocyte [Ca2+]i, [Mg2+]i and [H+]i, and buffering intracellular pH reduces the 
[Ca2+]i and [Mg2+]i increases, showing that these are evoked by the rise of [H+]i. The H+-
gated [Ca2+]i elevation is mediated by channels with characteristics of TRPA1, being 
inhibited by ruthenium red, isopentenyl pyrophosphate, HC-030031, A967079 or 
TRPA1 knockout. TRPA1 block reduces myelin damage in ischaemia. These data 
suggest TRPA1-containing ion channels as a therapeutic target in white matter 
ischaemia.  
 Ischaemia blocks action potential propagation through myelinated axons1. Electron 
microscopy2 and imaging of dye-filled oligodendrocytes3 show ischaemia-evoked Ca2+-
dependent damage to the capacitance-reducing myelin sheaths, which causes loss of action 
potential propagation. Glutamate receptor block reduces myelin damage and action potential 
loss2-7, and glutamate evokes a membrane current in oligodendrocytes mediated by 
AMPA/kainate and NMDA receptors2-4. Thus, oligodendrocyte damage is thought to be 
excitotoxic: as for neurons in ischaemia, a rise of glutamate concentration8 caused by reversal 
of glutamate transporters in oligodendrocytes and axons9,10 activates receptors that raise2 
oligodendrocyte [Ca2+]i, thus damaging the cells.  
 However, although AMPA/KA and NMDA receptors regulate oligodendrocyte 
precursor development11,12, these receptors are down-regulated as the cells mature13-15. How 
can mature oligodendrocytes be damaged excitotoxically, if they express low levels of 
glutamate receptors? To investigate how oligodendrocyte [Ca2+]i is raised in ischaemia, we 
 3
characterised ischaemia-evoked membrane current and [Ca2+]i changes in cerebellar white 
matter oligodendrocytes.   
 Solution mimicking ischaemia (see Methods) evoked an increasing inward current in 
oligodendrocytes (Fig. 1a-b), often with a faster phase that was obscured when responses in 
many cells were averaged (Fig. 1c). When applied from before the ischaemia, NBQX and D-
AP5 reduced the ischaemia-evoked current by 66% (Fig. 1c-d), while mGluR block had no 
effect (Ext. Data Fig. 1a). Preloading for 30 mins with the glutamate transport blocker PDC, 
to prevent ischaemia-evoked glutamate release by reversal of transporters in the white9 and 
grey16 matter, also reduced the inward current (by 68%, Fig. 1c-d), while blocking other 
candidate release mechanisms had no effect (Ext. Data Fig. 1a). Thus, glutamate release by 
reversed uptake helps to trigger the ischaemia-evoked current. Strikingly, however, current 
flow through glutamate receptors generates only a small fraction of the sustained inward 
current evoked by ischaemia, since applying NBQX and D-AP5 from 200 sec after ischaemia 
had started produced only a non-significant 21% suppression of the ischaemia-evoked inward 
current (Fig. 1d).  
In neurons, an ischaemia-evoked inward current triggered by glutamate release, but 
maintained by non-glutamatergic mechanisms, generates the “Extended Neuronal 
Depolarization” (END) that evokes neuronal death17. However, the ischaemia-evoked current 
in oligodendrocytes was not prevented by removing external Ca2+, nor by gadolinium, which 
both block the END17 (Fig. 1d-e), implying a different mechanism maintains the inward 
current triggered by glutamate. 
 Unlike in neurons, where ischaemia evokes a conductance increase mediated by 
ionotropic glutamate receptors16, ischaemia decreased the conductance of oligodendrocytes 
(Fig. 1f-g). The suppressed current reversed below the K+ reversal potential (EK=-104 mV), at 
-121 mV with 10 mM (Fig. 1f, Ext. Data Fig. 1e) and -118 mV with 0.5 mM HEPES (Fig. 
1g). This is expected if ischaemia decreases the membrane K+ conductance, while [K+]o rises 
(due to Na+/K+ pump inhibition throughout the slice) which increases the inward current at all 
potentials (see Ext. Data Fig. 1b-d; Suppl. Information). K+-sensitive electrodes showed that 
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[K+]o in the white matter initially rose slowly during ischaemia, but then increased more 
abruptly, in parallel with the membrane current (Fig. 1h). The peak rise was 2.35+0.13 mM 
(n=12) in the white matter and 2.48+0.35 mM (n=4) in the adjacent grey matter (where it 
reflects the anoxic depolarization of neurons18). The conductance decrease described above 
produced 32%, while the [K+]o rise produced 68%, of the inward current in oligodendrocytes 
at -74mV (see Suppl. Information). Thus, changes in K+ fluxes generate the ischaemia-evoked 
inward current. 
 Could part of the NMDA-evoked inward current in oligodendrocytes4 also reflect a 
[K+]o rise? Extracellular Cs+ blocked the NMDA-evoked current while intracellular MK-801 
had no effect (Ext. Data Fig. 2a-d), suggesting most of the NMDA-evoked current is 
generated by [K+]o rising, rather than by oligodendrocyte NMDA receptors. Applying NMDA 
or raising [K+]o, and correlating the resulting inward current with the [K+]o rise occurring (see 
Supplementary Information; Ext. Data Fig. 2e-f), we found that at least 49% of the NMDA-
evoked current was attributable to the [K+]o rise that it produced. Since mature 
oligodendrocytes express few NMDA receptors13-15, this presumably reflects NMDA 
depolarizing neurons or astrocytes in the slice and releasing K+. 
 These data challenge the idea2-5 that, during ischaemia, NMDA receptors in mature 
oligodendrocytes generate a prolonged calcium influx which damages the cells. We therefore 
investigated the ion concentration changes evoked in oligodendrocytes by activation of 
NMDA receptors, using Ca2+-, Na+- and K+-sensitive dyes loaded into cells from the pipette. 
When 100 µM NMDA was applied to whole-cell clamped cerebellar granule neurons at -74 
mV, as expected it evoked an inward current, and raised [Ca2+]i and [Na+]i (Ext. Data Fig. 3). 
In contrast, although NMDA evoked an inward current in oligodendrocytes, it generated no 
[Ca2+]i or [Na+]i elevation, indeed [Na+]i decreased after applying NMDA (Fig. 2a). NMDA 
raised [K+]i however. Similar concentration changes were seen at the soma (Fig. 2a) and in 
the internodal processes where NMDA receptors may be located2-4 (Fig. 2b). Like NMDA, 
raising [K+]o lowered [Na+]i (Fig. 2a, b). A likely explanation is that NMDA raises [K+]o (Fig. 
2c), which decreases [Na+]i by activating the Na+/K+ pump. 
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  The absence of a rise of [Ca2+]i and [Na+]i is surprising if oligodendrocytes express 
NMDA receptors2-4. Conceivably NMDA receptors might pass ions into a compartment in 
their myelinating processes which only certain Ca2+-sensing dyes such as X-Rhod-1 can 
access2. However, whether X-Rhod-1 was loaded as an acetoxymethyl ester2 or from the 
pipette, we observed no NMDA-evoked change of [Ca2+]i in the myelinating processes (Fig. 
2d). Nevertheless, we could detect spontaneous [Ca2+]i rises propagating through myelinating 
processes in 55% of oligodendrocytes (Fig. 2e). 
 To confirm that ischaemia raises2 oligodendrocyte [Ca2+]i, we loaded the Ca2+-sensing 
dye Fluo-4 (with Alexa Fluor 594, for ratiometric imaging) into oligodendrocytes from a 
whole-cell pipette (in current-clamp mode, allowing voltage changes, in case voltage-gated 
Ca2+ channels raise [Ca2+]i). Ischaemia increased [Ca2+]i in the soma and processes over ~10 
mins. This was abolished if extracellular calcium was removed (Fig. 3a-b), and reduced by 
removing external K+ (Fig. 3c), suggesting that the ischaemia-evoked [K+]o rise promotes 
calcium entry from the extracellular solution. However, contradicting the earlier report2, 
blocking NMDA receptors with MK-801, D-AP5 and 7-chloro-kynurenate, or blocking 
NMDA and AMPA/KA receptors with NBQX and D-AP5 while blocking voltage-gated Na+ 
and Ca2+ channels and GABAA receptors, did not prevent the [Ca2+]i rise (Fig. 3a-b). 
Similarly, when PDC-preloading reduced transporter-mediated glutamate release, the [Ca2+] 
rise was unaffected (Fig. 3c).  
Similar experiments using a Mg2+-sensitive dye revealed that [Mg2+]i also rises in 
ischaemia (Fig. 3d). This was not due to ATP breakdown, which releases Mg2+, since the 
[Mg2+]i rise was abolished by removing extracellular Mg2+ (Fig. 3d) implying that Mg2+ enters 
across the cell membrane. Surprisingly, ischaemia did not raise [Na+]i (Fig. 3e). Thus 
ischaemia activates a membrane conductance that allows entry of divalent ions.   
 Seeking an agent that decreases membrane K+ conductance and activates Ca2+ entry, 
we measured the ischaemia-evoked pH change in oligodendrocytes. Ischaemia increased [H+]i 
on the timescale seen for [Ca2+]i (Fig. 3f). A similar (but smaller) [H+]i rise was evoked by 
elevated [K+]o or NMDA (Ext. Data Fig. 4a), suggesting that the ischaemia-evoked [K+]o rise 
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partly generates this pH change. To investigate this, we removed external K+, which reduced 
the [K+]o in the slice from 2.46+0.02 mM (n=13) to 0.99+0.3 mM (n=4) (Mann-Whitney 
p=0.001, Fig. 3g), and hyperpolarized the resting potential by 7 mV (-84.0+4.7 to -77.2+4.3 
mV, n=4, p=0.002, paired t-test, Fig. 3g). The ischaemia-evoked [K+]o rise and depolarization 
were unaffected by K+ removal (Fig. 3g), but the [H+]i initially and during ischaemia were 
reduced (Fig. 3h). These data and those in Fig. 3c suggest that the ischaemia-evoked [K+]o 
rise helps to acidify the cell, which in turn evokes Ca2+ entry.  
 Using an internal solution containing 50 mM HEPES, the ischaemia-evoked rise of 
[H+]i was, as expected, greatly reduced (Fig. 3f). This prevented the decrease of K+ 
conductance (Figs. 1g, 3i), consistent with intracellular acidity suppressing activity of 
tonically-active K+ channels19. Strikingly, however, buffering intracellular pH also prevented 
the ischaemia-evoked rise of [Ca2+]i and [Mg2+]i (Fig. 3j-k), implying that the ischaemia-
evoked [H+]i rise activates entry of these cations into the cell. Consistent with this, uncaging 
protons in oligodendrocytes raised [Ca2+]i and [Mg2+]i (Fig. 3l-m). 
 Few channels allow entry of Ca2+ and Mg2+ better than Na+, but many TRP channels 
share this property20 (and TRP channel activation can cause ischaemic damage to neurons21 
and astrocytes22). Of these channels, only20,23,24 TRPA1 and TRPV3 are known to be activated 
by intracellular H+, so we applied modulators of these channels and examined the effect on 
oligodendrocyte [Ca2+]i (TRP agonist and blocker specificity are discussed in Supplementary 
Information). The TRPA1/TRPV3 blocker isopentenyl pyrophosphate25 (IPP) and the TRPA1 
blocker26 HC-030031 slowed and reduced the [Ca2+]i rise evoked by uncaging H+ in the cell 
(Fig. 3l). The TRPA1/TRPV3 agonists20,27 menthol, vanillin, carvacrol (Cv) and 2-APB all 
raised [Ca2+]i in oligodendrocyte somata and myelinating processes, as did the TRPA1 
agonists27 AITC, polygodial and flufenamic acid, while the TRPV3 agonists20,27 camphor and 
farnesyl pyrophosphate (FPP) did not (Fig. 4a-b). Thus, TRPA1 subunit-including channels 
contribute to these responses, but TRPV3 channels are not needed. The carvacrol-evoked rise 
of [Ca2+]i was reduced by HC-030031 which blocks TRPA1 but not TRPV326, by the 
TRPA1/TRPV3 blocker isopentenyl pyrophosphate25 (IPP), and by TRPA1 knock-out (Fig 
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4b), again implying involvement of TRPA1 channels. It was unaffected by buffering [H+]i 
(Fig. 4b), consistent with Ca2+ entry via TRPA1 being downstream of the [H+]i rise, as seen 
with H+ uncaging (Fig. 3l). 
Using in situ hybridization, a TRPA1 probe labelled cerebellar white matter in rat and 
mouse, while a TRPV3 probe labelled rat only (Ext. Data Fig. 5a). Immunocytochemistry 
revealed that TRPA1- and TRPV3-expressing cells included myelinating oligodendrocytes 
expressing Olig2 and CC1 (Ext. Data Fig. 5b-d).  
 Consistent with ischaemia raising [Ca2+]i by activating TRPA1- rather than TRPV3-
containing channels, the general TRP blockers20,27 ruthenium red (RuR, 10 μM) and La3+ (1 
mM) and the TRPA1/TRPV3 blocker25 IPP (200 μM) reduced the [Ca2+]i rise, as did HC-
030031 and A967079, which block TRPA1 but not TRPV326,28  (Fig. 4c-e). Knock-out of 
TRPA1 slowed and halved the ischaemia-evoked [Ca2+]i rise, and the TRPA1/TRPV3 blocker 
IPP produced no further reduction in the knock-out (suggesting no contribution of TRPV3: 
Fig. 4f), while knock-out of TRPV3 did not affect the [Ca2+]i rise, and the TRPA1 blocker 
HC-030031 slowed and halved the rise occurring in the TRPV3 knock-out (Fig 4g). Blockers 
of many other TRP channels had no effect (Ext. Data Fig. 6). Thus TRPA1 is the dominant 
contributor to the ischaemia-evoked rise of [Ca2+]i in oligodendrocytes.  
The larger (70%) block of the ischaemia-evoked [Ca2+]i rise by the TRPA1 blocker 
HC-030031 than by TRPA1 knock-out (50%: Figs. 4e-f) suggests there may be compensatory 
upregulation of another Ca2+ entry pathway in the TRPA1 knock-out, which normally 
generates only ~30% of the [Ca2+]i rise. Introducing high pH-buffering-power solution into 
the cell blocked the [Ca2+]i rise in the TRPA1 knock-out (Fig. 4h), implying that the non-
TRPA1 Ca2+ entry pathway is also H+-activated. Since the non-specific TRP blockers RuR 
and La3+ abolished the ischaemia-evoked [Ca2+]i rise, these data suggest there is another Ca2+-
permeable TRP channel (neither TRPA1 nor TRPV3) which is activated by internal H+ in 
oligodendrocytes and generates ~30% of the ischaemia-evoked [Ca2+]i rise. 
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To assess the role of TRPA1-containing channels in evoking myelin damage, we 
exposed rat optic nerves to 60 mins ischaemia. This led to disruption of myelin sheaths2,3, 
which we quantified by counting the regions of myelin decompaction (lamellar separation) 
per axon cross section (see Methods). Taking as baseline the level of decompaction which 
occurs in control nerves during processing for EM, ischaemia increased decompaction 
(p=3x10-8), and ruthenium red or the TRPA1 blockers HC-030031 and A967079 (applied 
together) reduced this increase by 69% (p=3x10-5) and 59% (p=2.0x10-5) respectively (Fig. 4i-
j). Ischaemia did not affect the axon g ratio (Fig. 4k: see Methods), but increased axon 
diameter via swelling (Fig. 4l). It also caused some axon vacuolization (Fig. 4m): vacuoles 
were seen in 4.3% of 2390 control axons, but in 21% of 15976 axons after ischaemia. 
Vacuolization was not prevented by TRP channel block (Fig. 4m), suggesting different 
mechanisms for axon and myelin damage. 
 Thus, ischaemic damage to oligodendrocytes differs fundamentally from that in 
neurons (Ext. Data Fig. 7), where [Ca2+]i is raised by glutamate-gated receptors (and later by 
TRP channels activated by reactive oxygen species21). Contradicting current ideas2-4, 
ischaemia does not damage oligodendrocytes by activating Ca2+ entry through ionotropic 
glutamate receptors in their membranes. Instead, ischaemia-evoked sodium pump inhibition 
and glutamate release evoke a long-lasting rise of [K+]o that, together with metabolic changes, 
acidifies the oligodendrocyte, activating H+-gated TRP channels through which Ca2+ enters.  
In the optic nerve, ischaemia-evoked Ca2+ entry into oligodendrocytes is blocked by 
NMDA receptor antagonists2, contradicting our demonstrations that NMDA evokes no [Ca2+]i 
rise in oligodendrocytes (Fig. 2) and that the ischaemia-evoked [Ca2+]i rise is unaffected by 
NMDA receptor blockers (Fig. 3). Conceivably, in the optic nerve, NMDA receptors on 
astrocytes29 make a greater contribution than in cerebellum to generating the ischaemia-
evoked rise of [K+]o and thus the [Ca2+]i rise. 
TRPA1 generates ~70% of the ischaemia-evoked [Ca2+]i rise, and TRPA1 blockers 
reduce ischaemic damage to myelin (Fig. 4). Consequently, blocking oligodendrocyte 
TRPA1-containing channels may reduce myelin loss during the energy deprivation that 
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follows stroke, secondary ischaemia caused by spinal cord injury, or hypoxia in multiple 
sclerosis30. 
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Figure Legends 
Figure 1. Ischaemia evokes an inward current in oligodendrocytes by altering K+ fluxes. 
a Whole-cell clamped oligodendrocyte. Inset: Alexa dye in processes around an axon. b 
Ischaemia-evoked membrane current in single cell. c Current in 179 control cells, 12 cells 
exposed to 25 μM NBQX and 200 μM D-AP5 from before ischaemia, or 9 cells preloaded16 
with 1 mM PDC. d Current (normalised to interleaved control cells) from 8-10 mins after 
start of ischaemia in cells preloaded with PDC, exposed to NBQX+AP5 throughout ischaemia 
or from 200 sec after ischaemia starts, or exposed to NBQX or AP5 alone or to zero-Ca2+ 
solution (with 50 μM EGTA) throughout ischaemia. Mann-Whitney p values compare with 
control cells; cell numbers shown on bars. e Effect of Gd3+ (100 μM) on ischaemia-evoked 
current at 8-10 mins (Mann-Whitney p=0.83). f I-V relation of 10 cells before and after 5 
mins ischaemia (10 mM HEPES internal). g Ischaemia-evoked current in 10 cells with 0.5 
mM and 9 cells with 50 mM internal HEPES. Ischaemia decreased cell conductance by 
2.1+0.7 nS near -70 mV in 11 cells using 10 mM, and by 2.3+0.6 nS in 10 cells using 0.5 
mM, internal HEPES; 50 mM HEPES abolished the decrease (Fig. 3i). h Change of [K+]o in 
grey matter (GM, granule cell layer), and in white matter (WM, different slice) with 
simultaneously recorded oligodendrocyte current. Error bars, s.e.m. 
Figure 2. NMDA does not elevate [Ca2+]i in oligodendrocytes.  
a-b Oligodendrocyte membrane current (lower traces, a) and background-subtracted 
fluorescent dye ratio (R, see Methods, concentration increases are upwards for all dyes) when 
measuring [Ca2+]i with Fura-2, [Na+]i with SBFI, and [K+]i with PBFI; 100 μM NMDA was 
applied, or [K+]o was raised from 2.5 to 5 mM, with fluorescence measured in soma (a) or 
myelinating processes (b). Right panels: peak fluorescence change normalised to evoked 
current (number of cells on bars). c NMDA-evoked current and simultaneously recorded 
[K+]o. d Measuring [Ca2+]i with X-Rhod-1, loaded from pipette or as an acetoxymethyl ester2, 
reveals no NMDA-evoked [Ca2+]i rise. e Spontaneous [Ca2+]i transients in four myelinating 
processes confirm Fura-2 is working. Error bars, s.e.m. 
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Figure 3. Ischaemia evokes a [Ca2+]i and [Mg2+]i rise gated by internal protons. 
a Ratiometric Fluo-4/Alexa-Fluor-594 signals ([Ca2+]i) and membrane potential (Vm) in 
oligodendrocytes exposed to ischaemia (starting at arrow), or ischaemia in zero [Ca2+]o, or 
with drugs at concentrations (μM): AP5 50, MK-801 50, 7-chlorokynurenate (7CK) 100, 
NBQX 25, GABAzine (Gz) 20, TTX 1, Cd2+ (to block Ca2+ channels) 100. b Mean data from 
experiments like a (cell numbers on bars; p values compare with soma or process control 
values). c Data as in a after PDC-preloading or in 0 mM [K+]bath. d Ischaemia-evoked [Mg2+]i 
rise monitored with Mag-Fluo-4 in normal and Mg2+-free solution. e Ischaemia-evoked [Na+]i 
change monitored with SBFI (6 cells). f Ischaemia-evoked [H+]i rise monitored with BCECF 
with 0.5 mM and 50 mM internal HEPES (p from Mann-Whitney test). g [K+]o and 
oligodendrocyte membrane potential (Vm) with 2.5 or 0 mM [K+]bath, before (Resting) and 
during ischaemia (Isch peak), and change produced by ischaemia (ΔIsch). h Effect of 
removing K+ from bath solution on [H+]i in control conditions (relative to value at start of K+ 
removal), and [H+]i increase evoked by ischaemia (normalised to value at start of ischaemia) 
with 2.5 or 0 mM bath K+. i High [HEPES]i blocks ischaemia-evoked decrease of membrane 
conductance. j-k Ischaemia-evoked rise of [Ca2+]i (j) and [Mg2+]i (k) are inhibited with 50 
mM internal HEPES. l-m Uncaging H+ with light (bars) raises [Ca2+]i (l, an effect reduced by 
200 μM  IPP or 80 μM HC-030031) and [Mg2+]i (m), but not when caged H+ is omitted from 
the pipette. P values in l from Mann-Whitney tests. Error bars, s.e.m. 
Figure 4. TRPA1-containing channels mediate ischaemic Ca2+ accumulation and myelin 
damage.  
a [Ca2+]i change (measured with Fluo-4/Alexa-Fluor-594) in soma (black) or processes 
(white) evoked by TRPA1/TRPV3 agonists (mM): menthol 2, vanillin 1, 2-APB 2, TRPV3 
agonists (camphor 2, FPP 0.5) and TRPA1 agonists AITC (0.5), FFA (1) and polygodial 
(0.2). b Rise of [Ca2+]i evoked by the TRPA1/TRPV3 agonist carvacrol (2 mM, in 1 μM TTX 
to avoid effects of altered neuronal spiking) is inhibited by the TRPA1/TRPV3 antagonist 
isopentyl pyrophosphate (IPP, 200 μM, Mann-Whitney test on soma data), the TRPA1 
 16
antagonist HC-030031 (80 μM), and by TRPA1 knock-out (Mann-Whitney test on process 
data), but not by 50 mM internal [HEPES] (p values compare with soma or process control 
value). c-d Ischaemia-evoked [Ca2+]i rise is blocked by Ruthenium Red (RuR, 10 μM, 
measured with Fura-2) (c), and by La3+ (d, 1 mM, measured with Fluo-4/Alexa 594, using 
HEPES-buffered external solution to avoid precipitation, Mann-Whitney test on soma data). e 
Block of ischaemia-evoked [Ca2+]i rise (measured with Fluo-4) by TRPA1/TRPV3 blocker 
IPP (200 μM) and by TRPA1 blockers HC-030031 (80 μM) and A967079 (10 μM). Mann-
Whitney p values compare with soma or process control values. f Ischaemia-evoked [Ca2+]i 
rise in wild-type mice, with TRPA1 knocked out (process data showed same trend as the 
soma but with p=0.07) and with the TRPA1/TRPV3 blocker IPP (200 μM) present in the KO. 
g Ischaemia-evoked [Ca2+]i rise in wild-type mice, with TRPV3 knocked out and with the 
TRPA1 blockers HC-030031 (80 μM) and A967079 (10 μM) present in the KO (Mann-
Whitney p values). h Ischaemia-evoked [Ca2+]i rise in TRPA1 KO with 10 mM and 50 mM 
internal [HEPES]. i Specimen EM pictures showing control optic nerves and myelin 
decompaction (white arrows) in nerves exposed to ischaemia or ischaemia in RuR (10 μM), 
or A967079 (10 μM) and HC-030031 (80 μM) applied together for 60 mins (TRPA1 block). 
j-m Lamella separations (j), g ratio (k), axon diameter (l) and axon vacuoles (m: EM picture 
shows vacuoles (black arrows) forming within axon and periaxonal space during ischaemia) 
in control, ischaemia alone or ischaemia with RuR (10 μM) or with A967079 (10 μM) and 
HC-030031 (80 μM) (TRPA1 block). Numbers on bars are ‘images (axons)’. P values for j-m 
from Mann-Whitney tests except l from Kolmogorov-Smirnov test. Error bars, s.e.m. 
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Methods 
Animals 
Experiments used Sprague-Dawley rats or transgenic mice of either sex. Animal 
procedures were carried out in accordance with the guidelines of the UK Animals (Scientific 
Procedures) Act 1986 and subsequent amendments. TRPV3 knock-out (KO) mice were 
obtained from JAX (http://jaxmice.jax.org/strain/010773.html). TRPA1 KO mice were 
obtained as a double knock-out with TRPV1 knocked out (kindly provided by John Wood and 
Jane Sexton). TRPV1 does not contribute to the ischaemia-evoked [Ca2+]i rise described here 
because the TRPV1 antagonist20,27 capsazepine did not reduce the ischaemia-evoked [Ca2+]i 
rise in rat oligodendrocytes (Ext. Data Fig. 6a) and the TRPV1 agonists20,27 capsaicin (10 μM) 
and camphor (2 mM) did not evoke a [Ca2+]i rise (see Specificity of drugs acting on TRP 
channels and Fig. 4a). Wild type and (double) KO mice were obtained from a colony 
obtained by breeding mice doubly heterozygous for the TRPA1 and TRPV1 knock-outs. The 
wild-type and KO mice compared share the same doubly heterozygous grandparents. 
Brain slice preparation 
Cerebellar slices (225 μm thick) were prepared from the cerebellum of P12 rats in 
ice-cold solution containing (mM) 124 NaCl, 26 NaHCO3, 1 NaH2PO4, 2.5 KCl, 2 MgCl2, 2-
2.5 CaCl2, 10 glucose, bubbled with 95% O2/5% CO2, pH 7.4, as well as 1 mM Na-
kynurenate to block glutamate receptors. Slices were then incubated at room temperature (21–
24°C) in the same solution until used in experiments. Cerebellar slices from P10-17 mice 
were prepared in ice-cold solution containing (mM) 87 NaCl, 25 NaHC03, 1.25 NaH2PO4, 2.5 
KCl, 7 MgCl2, 0.5 CaCl2, 25 glucose, 75 sucrose, 1 Na-kynurenate and then transferred to the 
same solution at 27°C and allowed to cool naturally to room temperature. Only 1 cell was 
recorded from in each slice. 
Cell identification and electrophysiology  
Oligodendrocytes, cerebellar granule cells and hippocampal pyramidal cells were 
identified by their location and morphology. All cells were whole-cell clamped with pipettes 
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with a series resistance of 8-30 MΩ. Electrode junction potentials were compensated. I-V 
relations were from responses to 200 msec voltage steps. Unless otherwise indicated, cells 
were voltage-clamped at -74 mV. 
External solutions  
Slices were superfused with either bicarbonate-buffered solution containing (mM) 
124 NaCl, 2.5 KCl, 26 NaHCO3, 1 NaH2PO4, 2-2.5 CaCl2, 1 MgCl2, 10 glucose, pH 7.4, 
bubbled with 95% O2 and 5% CO2, or with HEPES-buffered solution containing (mM) 144 
NaCl, 2.5 KCl, 10 HEPES, 1 NaH2PO4, 2-2.5 CaCl2, 1 MgCl2, 10 glucose, pH set to 7.3 with 
NaOH, bubbled with 100% O2. During experiments when NMDA was applied and ion 
concentration changes were observed with ion sensitive dyes, MgCl2 was omitted from the 
solution to minimize the Mg2+ block. For experiments involving Gd3+ and La3+, the HEPES-
based solution was used and NaH2PO4 was omitted. To simulate ischaemia we replaced 
external O2 with N2, and external glucose with 7 mM sucrose, added 2 mM iodoacetate to 
block glycolysis, and 25 μM antimycin to block oxidative phosphorylation31,4. All ischaemia 
experiments were done at 33-36°C, while applications of NMDA and of TRP channel 
agonists were at 24oC. Control and drug conditions were interleaved where appropriate. For 
calcium imaging experiments when applying ischaemia solution to brain slices from 
transgenic mice, the experimenter was blind to the genotype.  
Intracellular solutions 
Cells were whole-cell clamped with electrodes containing either Cs- (to improve 
voltage uniformity) or K-gluconate-based solution, comprising (mM) 130 Cs-gluconate (or K-
gluconate), 2 NaCl, 0.5 CaCl2, 10 HEPES, 10 BAPTA, 2 NaATP, 0.5 Na2GTP, 2 MgCl, 0.5 
K-Lucifer yellow, pH set to 7.2 with Cs- or K-OH (all from Sigma). The K+-based solution 
was used for current-clamp experiments. For Ca2+ imaging experiments, BAPTA was 
decreased to 0.01 mM and replaced with 10 mM phosphocreatine, added CaCl2 was reduced 
to 10 μM, and Lucifer Yellow was replaced with 1 mM Fura-2, or 200 µM Fluo-4 with 50 
µM Alexa Fluor 594, or 200 µM X-Rhod-1 with 50 µM Alexa Fluor 488 (all from Molecular 
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Probes) to allow ratiometric imaging. For imaging pH, Lucifer yellow was replaced with 
BCECF (96 μM) and the HEPES concentration was decreased to 0.5 mM. This [HEPES] was 
also used for control experiments when examining the effect of 50 mM internal [HEPES] on 
the ischaemia-evoked current; ischaemia-evoked membrane current changes were 
indistinguishable when 0.5 and 10 mM HEPES were used (see main text), presumably 
because endogenous pH buffering dominates at these low [HEPES] levels. For experiments 
where the pH-buffering capacity of the internal solution was increased, 68 mM K-gluconate 
and 50 mM HEPES were used. When uncaging protons, 2 mM 1-(2-nitrophenyl)ethyl 
sulphate sodium salt (NPE-caged protons, Tocris) was added to the pipette solution and 10 
mM HEPES was replaced by 30 mM Tris to prevent UV light-mediated oxidation32 of 
HEPES (and K-gluconate was reduced from 130 to 120 mM). For Na+ and K+ imaging 
experiments, Lucifer yellow was replaced with 1 mM of the Na+-sensing dye SBFI tetra-
ammonium salt or of the K+-sensing dye PBFI tetra-ammonium salt (Molecular Probes). In 
some experiments MK-801 (1 mM) was added to the internal solution to block NMDA 
receptors, and cells were depolarised to -10 mV for 10 sec intermittently over a 20 min 
waiting period to facilitate MK-801 block of open channels. 
Single cell ion imaging and H+ uncaging 
For Fura-2, SBFI and PBFI imaging when applying NMDA or during ischaemia, 
white matter oligodendrocytes and grey matter granule cells were patch-clamped with pipettes 
containing a solution as described above, fluorescence was excited sequentially at 340±10 nm 
and 380±10 nm, and emitted light was collected at 510±20 nm. The ratio (R) of the emission 
intensities (340 nm/380 nm), after subtraction of the background intensity averaged over 4 
distant areas of the image, was used as a measure of intracellular ion concentration. Increases 
of ion concentration generated a fall of fluorescence (F) excited at 380 nm and a rise in 
fluorescence excited at 340 nm, which is plotted as ΔR/R in the graphs shown, with R= 
F340nm/F380nm: an upward deflection corresponds to a rise of concentration of the sensed ion. 
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For Fura-2, SBFI and PBFI, mean values of R before applying NMDA or ischaemia solution 
were 0.41+0.05 (n=5), 1.68+0.14 (n=13) and 1.86+1.10 (n=8) respectively. 
Fluo-4 and Alexa Fluor 594 were used in the internal solution to measure [Ca2+]i 
changes ratiometrically during H+-uncaging and most ischaemia experiments. To measure 
[Mg2+]i  Mag-Fluo-4 was used instead of Fluo-4. Fluo-4 (or Mag-Fluo-4) and Alexa Fluor 594 
fluorescence were excited sequentially every 2, 10 or 30 seconds at 488±10nm and 
585±10nm, and emission was collected using a triband filter cube (DAPI /FITC/Texas Red, 
69002, Chroma). The mean ratio of intensities (F488nm/F585nm) before applying NMDA or 
ischaemia was 0.81+0.09 (n=16) for Fluo-4 and 0.55+0.04 (n=6) for Mag-Fluo-4. Caged-H+ 
were uncaged using 380±20 nm light for 1 second every 2 seconds (repeated 30 times) 
interspersed with the above excitation wavelengths. BCECF was imaged every 30 seconds at 
400 and 480nm, with emission collected using the above tri-band filter. The ratio (R) of the 
emitted light excited by these two wavelengths (F480nm/F400nm) was used as a measure of [H+]i 
(mean value before ischaemia was 17.6+0.9, n=8) but, since this ratio decreases with 
increasing [H+]i, when plotting changes in dR/R in Fig. 3e and Ext. Data Fig. 4 we multiplied 
them by -1 to produce a trace that increased with [H+]i. 
During ischaemia, slices swelled at the time of the anoxic depolarisation. When cells 
were patch-clamped with calcium dyes, the resulting movement of the cell away from the 
electrode sometimes caused [Ca2+]i oscillations within the cells. These oscillations did not 
occur if the patch pipette was removed (after 2 minutes to allow dye-filling) before the 
ischaemic solution was applied. Without the pipette attached to the cell, the time-course of the 
ischaemia-evoked [Ca2+]i rise was the same as with the electrode attached, but its amplitude 
was 69% larger (ratio increase 0.21+0.03, n=20 versus 0.12+0.02, n=16). In some 
experiments (those in Fig. 4c-g and Ext. Data Fig. 6) we therefore removed the pipette for 
calcium-imaging. 
Control experiments were carried out to check whether the ischaemia-evoked change 
of pH would affect our [Ca2+]i measurements. The internal solution for Ca2+-sensing was 
studied in the experimental bath that the slices usually are placed in. The resting ratio of Fluo-
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4 fluorescence to Alexa 594 fluorescence was not significantly affected by altering the pH of 
the solution from 7.05 to 6.55, and this also did not affect the change of ratio produced by 
adding 200 nM Ca2+ to the sensing solution (Ext. Data Fig. 4b, c). Thus, even a 0.5 unit pH 
change occurring in the oligodendrocyte would not significantly affect the calcium dye 
measurements. 
AM dye loading 
X-Rhod-1-AM (38 μM) dye loading with the myelin marker DIOC6 into P12 
cerebellar slices was performed as described previously for optic nerves2. Loading times 
ranged from 1-2 hrs and a de-esterification period of 30 mins at 36°C was allowed before 
imaging. 
Potassium electrodes 
Potassium electrodes were made as described33. Electrodes were pulled with a 
resistance of 4-10 MΩ. Electrode tips were silanised by heating them to 250°C for 7 minutes 
whilst N2 and N,N-dimethyltrimethylsilylamine (Fluka) were gassed into the tip from the back 
of the electrode. The tip was then filled with either 6% valinomycin, 1.5% potassium 
tetrakis(4-chlorophenyl)borate (Fluka) and 92.5% 1,2-dimethyl-3-nitrobenzene (Fluka) or the 
pre-made potassium sensitive ionophore I – cocktail B (Fluka). The electrodes were back-
filled with the bicarbonate-buffered external solution mentioned above (2.5 mM K+), and 
attached to a sensitive high resistance electrometer (Model FD 223, World Precision 
Instruments). A reference electrode tip was placed less than 5 µm away from the K+ electrode 
tip, and the voltage changes measured by it were subtracted from those measured with the K+ 
electrode. [K+]o was determined by calibrating each electrode at the end of every experiment 
with at least 3 different K+ concentrations (1, 2.5, 5, 7.5, 10 or 17.5 mM). To check for cross-
reactivity, the [NaCl]o was decreased by 60 mM which led to a -2.2±0.1 mV change in 
voltage (n=3), while a pH change from 7.3 to 6.5 led to a 0.47±0.22 mV change (n=3). Both 
of these changes are much less than the 17.5+0.5 mV change (n=18) seen in response to an 
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increase of [K+]o from 2.5 to 5 mM (which is consistent with the electrodes used having an 
average calibration slope of 60.9±0.9 mV (n=6) per 10-fold change of [K+]o).  
Drugs used 
Stock solutions of the following drugs were made up in water: NMDA, AP5, NBQX, 
MK801, 7-CK, TTX, PDC, IPP, CPG, SKF 96365 and RuR. (S)-MCPG and amiloride were 
made up in external solution. Carvacrol was made up in ethanol. Bicuculline, bumetanide, HC 
030031, A967079, flufenamic acid, capsazepine, FTY720-HCl, 2-APB, AITC, RN1734 and 
ML204 were made up in DMSO. When used, DMSO and ethanol were also added to control 
solution at the same concentrations, and did not evoke [Ca2+]i changes at the concentrations 
used. Stocks were kept at -20oC apart from carvacrol, menthol, vanillin, AITC, and RuR, 
which were made up fresh on each day of use. To minimise evaporation of carvacrol, vanillin 
and menthol, lids were kept on until the solutions were used. Gd3+ and La3+ were applied (as 
chloride salts) in bicarbonate- and phosphate-free solution to avoid chelation by these anions 
(see External Solutions above).  
Immunohistochemical labelling of oligodendrocytes 
Cerebellar slices were fixed for 30 mins in 4% PFA, and incubated for 1 to 6 h in 
0.1% Triton X-100, 10% goat serum in phosphate-buffered saline at 21°C, then with primary 
antibody at 4°C overnight with agitation, and then 2 hours or overnight at 24°C with 
secondary antibody. Primary antibodies were: anti-CC1 (mouse, 1:300, Calbiochem OP80 
monoclonal) and anti-Olig-2 (rabbit, 1:700, Millipore, AB9610 polyclonal). Secondary 
antibodies were: goat anti-rabbit AlexFluor 488 or 568 (Molecular Probes, 1:1000), donkey 
anti-rabbit AlexFluor 488 (Millipore, 1:1000), and goat anti-mouse Alexa Fluor 568 
(Millipore, 1:1000). 
Antibody labelling and in situ hybridization for TRPA1 and TRPV3 
TRPA1 and TRPV3 antibodies appeared to label the myelinating processes and 
somata of oligodendrocytes in rat, but the labelling was not significantly different in wild-
type mice and mice with TRPA1 or TRPV3 knocked-out (data not shown). We therefore 
turned to in situ hybridization.  
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Solutions used for in situ hybridization were pretreated with 0.1% DEPC. Animals 
were perfused with PBS followed by 4% PFA. Brains were post-fixed in 4% PFA overnight 
at 4°C, cryoprotected in 20% sucrose overnight at 4°C and frozen in Tissue-Tek O.C.T. 
Sections (20 μm) collected onto Superfrost Plus microscope slides (VWR International) were 
hybridized at 65oC overnight with hybridization buffer [50% v/v deionized formamide 
(Sigma), 10% w/v dextran sulphate (Fluka), 0.1 mg/ml yeast tRNA (Roche), 1x Denhardt’s 
solution (Sigma) and 1x “salts” (200 mM NaCl, 5 mM EDTA, 10 mM Tris-HCl pH 7.5, 5 
mM NaH2PO4, 5 mM Na2HPO4)] containing digoxigenin (DIG)-labelled antisense RNA 
probe (1:1000). Sections were washed with a washing solution (50% v/v formamide, 1× SSC, 
0.1% Tween 20) three times at 65°C for 30 min, followed by two 1× MABT (100 mM maleic 
acid, 150 mM NaCl, pH 7.5, 0.1% Tween-20) washes at room temperature for 30 min each. 
Sections were subsequently blocked with blocking solution [2% w/v Blocking Reagent 
(Roche Diagnostics), 10% v/v heat-inactivated sheep serum (Sigma) in 1× MABT] for 1 h at 
room temperature and incubated with anti-DIG antibody conjugated with alkaline 
phosphatase (AP) (Roche Diagnostics, 1:1500 in blocking solution) at 4°C overnight. 
Sections were then washed in 1× MABT 5 times for 20 min each at room temperature, 
followed by two 5 min washes in staining buffer (100 mM NaCl, 50 mM MgCl2, 100 mM 
Tris-HCl, pH 9.5, 0.1% Tween-20). Development was performed at 37°C for 24-48 hours 
overnight with nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate in freshly 
prepared staining solution (50% v/v staining buffer, 25 mM MgCl2, 5% w/v polyvinyl 
alcohol). Sections were washed in PBS and immunohistochemistry was performed as 
described above. The plasmids used to generate RNA probes were: IMAGE clone 40129486 
for Trpa1 (linearized with ClaI and transcribed with T3 RNA polymerase) and IMAGE clone 
40047664 for Trpv3 (linearized with XhoI and transcribed with SP6 RNA polymerase). In 
situ hybridization was repeated using at least three animals for each probe. 
Quantifying myelin decompaction during chemical ischaemia using electron microscopy 
 For chemical ischaemia experiments, optic nerves were dissected from P28 Sprague-
Dawley rats and incubated for 1 hour at 36°C in either control or ischaemic solution with and 
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without the TRPA1/V3 channel blocker ruthenium red (10 μM) or the combined presence of 
the TRPA1 blockers HC-030031 (80 μM) and A967079 (10 μM). The optic nerves were then 
immersion fixed in 2% paraformaldehyde and 2% glutaraldehyde in 0.1 M cacodylate buffer 
overnight. All samples were then post-fixed in 1% OsO4/0.1 M cacodylate buffer (pH 7.3) at 
3°C for 2 hours before washing in 0.1 M cacodylate buffer (pH 7.3). The samples were 
dehydrated in a graded ethanol-water series at 3°C and infiltrated with Agar 100 resin mix. 
The nerve was then cut transversely at the mid-point, blocked out and hardened. Ultra-thin 
sections were taken, 300 microns from the cut end of the middle of the nerve, on a Reichert 
Ultracut S microtome. Sections were collected on 300 mesh copper grids and stained with 
lead citrate. The sections were imaged using a Joel 1010 transition electron microscope and a 
Gatan Orius camera. 
 In 3 out of 4 experiments the experimenter was blinded to the drug condition prior to 
imaging (all 4 experiments gave similar results). One section was used from each nerve and 
eight 21.5 μm x 17.3 μm images were collected at x8000 magnification, four from the 
peripheral borders of the nerve at 0°, 90°, 180° and 270° positions on the section, and four 
covering the central portion of the nerve. In all experiments the image identities were then 
blinded prior to analysis, and the number of large separations of lamellae (decompaction) was 
counted. Decompaction was defined as a visible white inter-lamellar gap being present 
between at least 2 normal lamellae. Regions of decompaction were normally separated from 
each other by an area of compact myelin, but when most of the myelin surrounding an axon 
had separated lamellae, decompacted regions were counted at 0.5 micron intervals around the 
sheath. The number of decompacted regions was normalised to the number of axons per 
image. Some decompaction occurred even in control nerves as a result of the processing for 
electron microscopy, so we assessed drug block of decompaction by quantifying the 
ischaemia-evoked increase in decompactions seen without and with the drug present. Myelin 
g ratios were calculated as the square root of the ratio of the area of the axon to the area of the 
axon plus myelin sheath. When drawing lines around the axon and sheath, areas of 
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decompaction were ignored, i.e. we interpolated the lines from regions that were not 
decompacted. Axon diameter was calculated as (4.(axon area)/π)0.5. Axon vacuolisation was 
defined as the inclusion of one or more large (>0.1 µm) empty membrane bound (often 
circular) organelles within the axon or periaxonal space (Fig. 4m) which may reflect 
rearrangement of internal axonal membranes or be formed from inclusion of myelin 
membranes into the axon (Fig. 4m). 
Statistics 
 Data are presented as mean+s.e.m. Experiments were carried out on brain slices from 
at least 3 animals on at least 3 separate days, except for a few experiments using expensive 
drugs which were done on only 2 days. Only 1 cell was recorded from in each slice, so the 
numbers of cells given are also the numbers of slices. P values are from two tailed Student’s 
t-tests (for normally distributed data, assessed using Shapiro-Wilk tests) or Mann-Whitney U 
tests (for non-normally distributed data). Normally distributed data were tested for equal 
variance (p<0.05, unpaired F-test) and homo- or heteroscedastic t-tests were chosen 
accordingly. P values in the text are from unpaired t-tests unless otherwise stated. When small 
sample sizes (n<4) achieved p<0.05, analysis of sample and effect size typically demonstrated 
a power for detecting the observed effect of 80-99% (mean 92%), with two exceptions: the 
process data in Fig. 4c (power 78%) and the soma data in Fig. 4h (power 75%). For multiple 
comparisons within one experiment (usually one figure panel, but measurements of [Ca2+]i in 
somata and processes were treated as separate experiments even when plotted in the same 
figure panel), P values were corrected using a procedure equivalent to the Holm-Bonferroni 
method (for N comparisons, the most significant p value is multiplied by N, the 2nd most 
significant by N-1, the 3rd most significant by N-2, etc.; corrected p values are significant if 
they are less than 0.05). All statistical analysis was conducted using OriginLab software. 
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Extended Data Figure Legends 
Ext. Data Fig. 1. Tests for causes of the ischaemia-evoked current. 
a Effect of blocking various putative glutamate release mechanisms (blocker concentrations 
given in Supplementary Information) on peak ischaemia-evoked currents measured in the 
presence of each drug and in interleaved controls. No significant differences were measured 
(p>0.20). b Schematic showing effect of ischaemia-evoked decrease in resting conductance 
(which is dominated by gK, left) and ischaemia-evoked [K+]o rise (right) on oligodendrocyte 
membrane current. Black lines are control I-V relations. Red lines are I-V relations in 
ischaemia showing the effect of a conductance decrease (left) or of a positive shift of reversal 
potential due to [K+]o rising (right). c Ischaemia-evoked current change for the two 
mechanisms in b (cf. Fig. 1g).  d Sum of currents in c gives an I-V relation with a reversal 
potential more negative than EK. e Experimentally observed ischaemia-evoked current in 10 
oligodendrocytes with 10 mM internal HEPES (difference of curves in Fig. 1f). Error bars are 
s.e.m. 
Ext. Data Fig. 2. K+ flux changes generate the oligodendrocyte NMDA-evoked current. 
a-b Extracellular Cs+ (30 mM, replacing Na+) reduces the inward current evoked by 100 μM 
NMDA at -74 mV in oligodendrocytes (a), but not in hippocampal CA1 pyramidal neurons 
(b). c-d Intracellular MK-801 (1 mM) has no effect on NMDA-evoked currents in 
oligodendrocytes (c) but blocks them in pyramidal cells (d), while extracellular MK-801 (50 
μM) blocks both. e Voltage-dependence of the current evoked in 16 oligodendrocytes by 100 
μM NMDA and by elevating [K+]o from 2.5 to 5 mM. f Specimen plot of membrane current 
in an oligodendrocyte versus local [K+]o in response to applying 100 μM NMDA or elevating 
[K+]o from 2.5 to 5 mM. Horizontal cell line shows that if NMDA raises [K+]o to (say) 4.5 
mM, the current attributable to the [K+]o rise alone is 51% of the NMDA-evoked current. 
Mean value in 11 cells was 49% (see Supplementary Information). Error bars are s.e.m. 
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Ext. Data Fig. 3. NMDA-evoked ion concentration changes in neurons differ from those 
in oligodendrocytes 
a Specimen records of cerebellar granule cell membrane current and background-subtracted 
fluorescent dye ratio (R, see Methods) when measuring [Ca2+]i with Fura-2, [Na+]i with SBFI, 
and [K+]i with PBFI, when 100 μM NMDA was applied. The rise of [K+]i seen reflects K+ 
entry: [K+]pipette was 32.5 mM, so EK>-60mV for [K+]o >3.3 mM.  b Mean peak fluorescence 
change normalised to evoked current (number of cells on bars; p value from Mann-Whitney 
test). Oligodendrocyte data for comparison are shown in Fig. 2. Error bars are s.e.m. 
Ext. Data Fig. 4. Comparison of NMDA-, [K+]bath- and ischaemia-evoked changes of 
[H+]i. 
a Measurements of changes of ratio (R, see Methods) of background-subtracted BCECF 
fluorescence in oligodendrocytes in response to 100 μM NMDA and raising [K+]bath from 2.5 
to 5 mM with 0.5 mM internal HEPES, and to ischaemia with 0.5 mM and 50 mM internal 
HEPES. b-c Effect of pH of 10 mM HEPES internal solution on: (b) baseline ratio of Fluo-4 
to Alexa 594 fluorescence (p value from Mann-Whitney test), and (c) change of ratio when 
[Ca] was increased by 200 nM. Error bars are s.e.m. 
Ext. Data Fig. 5. In situ hybridization data on TRP channel expression.  
a. In situ data for TRPA1 and TRPV3 in the cerebellum of rats and mice show TRPA1 
mRNA in white matter (WM) cells in rats and mice (with denser expression in the adjacent 
granule cell layer, GCL), but TRPV3 mRNA only in white matter cells in rats. Specimen cells 
are labelled with white circles. b Higher magnification views of white matter, combining in 
situ hybridization for TRPA1 and TRPV3 with immunocytochemistry for Olig2 (to label 
oligodendrocyte lineage cells) and CC1 (to define myelinating oligodendrocytes). TRPA1 
mRNA is present (in rats and mice) and TRPV3 mRNA is present (in rats but not mice) in 
myelinating oligodendrocytes (Olig2+, CC1+: arrowheads) and also in some presumed 
oligodendrocyte precursor cells (Olig2+, CC1-: arrows). c-d Quantification of presence of 
mRNA for TRPA1 (c) and TRPV3 (d) in different oligodendrocyte lineage cell classes. 
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Numbers on bars are ‘images analysed (cells counted)’. P value from Mann-Whitney test. 
Error bars are s.e.m. 
Ext. Data Fig. 6. Further evidence for the identity of TRP channels in oligodendrocytes. 
[Ca2+]i increase (ratio signal from Fluo-4 and Alexa Fluor 594) in oligodendrocyte somata 
when ischaemia solution was applied with the following drugs present (data normalised to 
interleaved controls, shown as black bars): RN-1734 (0.5 mM), which blocks20,59 TRPV4 and, 
less well, TRPV1, TRPV3 and TRPM8; a cocktail of blockers inhibiting (see Supplementary 
Information section on Specificity of drugs acting on TRP channels) TRPP2, TRPC3, 
TRPC4, TRPC5, TRPC6, TRPC7, TRPM2, TRPM4, TRPM5, TRPV1, TRPV2, TRPM7, 
TRPM8 and TRPP1, as well as the store-operated calcium channel component STIM1 and 
some voltage-gated calcium channels; blocking voltage-gated Ca2+ channels with 10µM 
benidipine; or blocking reversed Na/Ca exchange with 10µM KB-R7943 mesylate (p values, 
from Mann-Whitney test and t-test as appropriate, were non-significant (p>0.28)). Error bars 
are s.e.m. 
Ext. Data Fig. 7. Schematic of how oligodendrocyte [Ca2+]i is raised in ischaemia. 
Run-down of transmembrane ion gradients leads to glutamate transporters (GluT) reversing 
(1) and releasing glutamate (2). This depolarizes (and causes a neurotoxic [Ca2+]i rise in) 
neurons (3) and raises [K+]o (4), causing an inward current (5) through oligodendrocyte K+ 
channels (KCh). At the same time, metabolic changes and also the rise of [K+]o lead to a rise 
in oligodendrocyte [H+]i (6). This decreases the membrane K+ conductance (either directly or 
via TRPA1-containing channels opening) which contributes to the inward current generated, 
and opens TRPA1-containing channels (7) that let Ca2+ and Mg2+ into the cell (8). The 
resulting rise of [Ca2+]i damages the myelin. 
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Supplementary Information 
Effect of internal cation on the ischaemia-evoked inward current in oligodendrocytes 
The peak inward current evoked by ischaemia (and its waveform) was not significantly 
different with Cs+ or K+ as the main pipette cation (209+10 pA, n=179, and 191+41 pA, n=10, 
respectively, p=0.67).  
Effect of blocking potential glutamate release mechanisms 
 In contrast to the suppressive effect of blocking glutamate release by reversed uptake, 
blocking other candidate mechanisms for glutamate release (from before the onset of ischaemia) did 
not affect the inward current significantly. Ext. Data Fig. 1a shows that there was no significant effect, 
when compared with interleaved control cells, on the peak ischaemia-evoked current of application 
of: 50 M bumetanide to inhibit NKCC1 transporters and prevent swelling of astrocytes leading to 
glutamate release34; 100 M CdCl2 to prevent exocytotic glutamate release driven by Ca2+ entry 
through voltage-gated Ca2+ channels35,36; 100 M lanthanum (LaCl3) to block glutamate release 
through gap junctional hemichannels37; 10 M BBG to block P2X7 receptors38; 100 M amiloride to 
block ASIC channels which may be activated by the acid shift occurring in ischaemia39,40; 1 M TTX 
to block action potential driven glutamate release35,36; 100 M bicuculline to block GABAA receptors, 
1 mM MCPG to block mGluRs, or 50 M CPG ((S)-4-carboxyphenylglycine) to block glutamate 
release by cystine-glutamate exchange41,42.  
Contribution of [K+]o rise and gK decrease to the ischaemia-evoked inward current 
 We assumed that the ischaemia-evoked current reflects the sum of the current produced by a 
rise of [H+]i suppressing a mainly K+-specific ohmic conductance with a conductance of 2.3 nS (the 
slope of the 0.5 mM HEPES line in Fig. 1g; the change of current this produces is schematised in Ext. 
Data Fig. 1b left panel), and a voltage-independent inward current of -58 pA (the mean value of the 
50 mM HEPES data in Fig. 1g) produced by the rise of [K+]o shifting the Nernst potential for K+ (the 
change of current this produces is schematised in Ext. Data Fig. 1b right panel). Together, these 
changes are expected to generate an ischaemia-evoked current which shows a conductance decrease 
and an apparent reversal potential more negative than the original value of EK (Ext. Data Fig. 1c-d) as 
is seen experimentally (Ext. Data Fig. 1e). For a mean input resistance of 148+23 M in 10 cells, this 
analysis implies that, on average, ischaemia reduced the resting conductance of the cell by 34%. Since 
the total inward current generated at -74 mV by the conductance decrease and the [K+]o rise was 85 
pA (Fig. 1f) and 58 pA of this was generated by the [K+]o rise, it follows that the conductance 
decrease generated 27 pA of inward current. Thus, the conductance decrease produced 32%, and the 
[K+]o rise produced 68% of the inward current at -74mV (at more positive potentials the contribution 
of the conductance decrease will be larger). 
A [K+]o rise and K+ influx mediate much of the response to NMDA 
 Since both ischaemia and application of glutamate or NMDA are expected to depolarize cells 
and release [K+]o, we compared the effects of 100 µM NMDA application to those of a small 
elevation of [K+]o. The oligodendrocyte response to a 2.5 mM elevation of [K+]o was strikingly similar 
to the response to NMDA, with a decrease of [Na+]i and an elevation of [K+]i (Fig. 2a, b) and no 
significant change in [Ca2+]i (-0.001+0.010 change in R, p=0.36). The I-V relation of both the NMDA 
and K+-evoked currents decreased towards zero above +25 mV (Ext. Data Fig. 2e). Consistent with a 
[K+]o rise-evoked K+ influx mediating a substantial part of the NMDA-evoked current, applying 30 
mM external Cs+ to block oligodendrocyte K+ channels reduced the NMDA-evoked current in 
oligodendrocytes by 88% (p=0.03, 7 cells), while having no effect on the NMDA-evoked current in 
hippocampal pyramidal cells (Ext. Data Fig. 2a, b). Conversely, including 1 mM MK-801 in the 
pipette to block NMDA receptors from the inside43 (and waiting 20 mins to allow the drug to diffuse 
through the cell) reduced the NMDA-evoked current in pyramidal cells by 88% (p=0.003, n=6), while 
having no effect on that in oligodendrocytes (Ext. Data Fig. 2c, d). Although this lack of effect might 
theoretically reflect the NMDA receptors in oligodendrocytes having an unusual subunit composition4 
which is not susceptible to block by internal MK-801, this is not likely because they are blocked by 
external MK-801 (Ext. Data Fig. 2c).  
 Using an extracellular K+-sensitive microelectrode to assess the [K+]o rise occurring near the 
patch-clamped oligodendrocyte when NMDA or an increase in [K+]o were applied (Fig. 1h), we found 
that 100 µM NMDA raised the local [K+]o by 1.52±0.17 mM (n=19), while switching from 2.5 mM to 
5 mM [K+] in the bath superfusate raised the local [K+]o by 2.32+0.18 mM near 21 cells. Plots of the 
membrane current change against local [K+]o during these responses (Ext. Data Fig. 2f) in 11 cells 
showed that the inward membrane current increased approximately linearly with the rise of [K+]o, 
with a slope that was 51% smaller (p=0.03) when increasing [K+] in the superfusate (-61.2±19.3 
pA/mM) than when applying NMDA (-124.0±46.1 pA/mM). These data suggest that a rise of [K+]o is 
responsible for 49% of the inward current, although the percentage could be significantly larger since 
the oligodendrocyte membrane is presumably closer than the K+-sensing electrode to the source of K+ 
when NMDA is applied than when the superfusate [K+] is raised.  
Specificity of drugs acting on TRP channels 
Both TRPA1 and TRPV3 have previously been suggested to play a role in the response of the 
CNS to ischaemia44,45. Unfortunately the pharmacology of TRP channels is complex, with many drugs 
acting non-specifically on different channels. Our conclusion that TRPA1 is the major contributor to 
raising [Ca2+]i in ischaemia is based on the following logic. 
(1) The ischaemia-evoked [Ca2+]i rise is abolished by removal of external Ca2+ and so reflects entry 
through an ion channel (Fig. 3a). 
(2) The general TRP channel blockers ruthenium red and La3+ block the ischaemia-evoked [Ca2+]i rise 
(Fig. 4c-d), suggesting the involvement of a TRP channel.  
(3) Other known intracellular targets of ruthenium red, such as ryanodine receptors and the 
mitochondrial uniporter, are unlikely to explain the actions of ruthenium red because, as stated above, 
the [Ca2+]i rise reflects Ca2+ entry from the extracellular space.  
(4) Voltage-gated Ca2+ channels, which are also targeted by ruthenium red and La3+, are not the source 
of the ischaemia-evoked [Ca2+]i rise since neither Cd2+ (Fig, 3b) nor benidipine (Ext. Data Fig. 6a) 
blocked the rise, and these channels are not Mg2+-permeable while ischaemia evokes entry of Mg2+ 
through the H+-gated channel (Fig. 3d, k). 
(5) The ischaemia-evoked [Ca2+]i rise is abolished (Fig. 3j) by reducing the ischaemia-evoked rise of 
[H+]i with a pH buffer (Fig. 3f), and so reflects entry through a H+-gated channel. 
(6) Of the TRP channels, only TRPA1 and TRPV3 are currently known to be activated by 
intracellular protons20,23,24. 
(7) Drugs that activate TRPA1 but not TRPV3 (polygodial, AITC, FFA), or that activate both TRPA1 
and TRPV3 (menthol, vanillin, carvacrol, 2-APB), but not drugs that activate TRPV3 and not TRPA1 
(FPP, camphor), elevate [Ca2+]i (Fig. 4a, b). The most specific TRPA1 agonist is polygodial which 
does not act46 on TRPV1, TRPV2, TRPV3, TRPV4 or TRPM8, followed by AITC (allyl-
isothiocyanate) which also acts20 on TRPV1. Flufenamic acid activates TRPA1 but inhibits TRPV1 
and TRPV347 and also acts on20,27,47-49 TRPC3, TRPC5, TRPC6, TRPC7, TRPV4, TRPV5, TRPV6, 
TRPM2, TRPM3, TRPM4, TRPM5 and TRPM8. Carvacrol activates TRPA1 and TRPV3, and 
inhibits TRPM720,27. Farnesyl pyrophosphate (FPP) activates TRPV3 but does not activate TRPV1, 
TRPV2, TRPV4, TRPA1, and TRPM825,50. Camphor activates TRPV3, activates TRPV1 and TRPM8, 
and inhibits TRPA120,27. Agonists for other TRPs (including 10 M capsaicin20,27 for TRPV1, 5 cells, 
not shown) did not raise [Ca2+]i detectably. Thus, activation of TRPA1, but not of TRPV3, raises 
oligodendrocyte [Ca2+]i. 
(8) The [Ca2+]i rise evoked by carvacrol (a TRPA1 and TRPV3 agonist, and TRPM7 blocker20,27) is 
blocked by the TRPA1/TRPV3 antagonist25 isopentenyl pyrophosphate (IPP), by the specific TRPA1 
antagonist51 HC-030031, and by TRPA1 knock-out (Fig. 4b). HC-030031 blocks TRPA1 without 
affecting TRPV1, TRPV3, TRPV4, TRPM8 or 48 other receptors, transporters and enzymes51. Thus, 
the blocker pharmacology matches that of the activator pharmacology. 
(8) Isopentenyl pyrophosphate and HC-030031 also reduce the [Ca2+]i rise evoked by uncaging of 
protons in oligodendrocytes (Fig. 3l), implying that TRPA1 is the main contributor to this response.  
(9) The specific TRPA1 blockers51,52 HC-030031 and A967079 greatly reduced the ischaemia-evoked 
[Ca2+]i rise (Fig. 4e). HC-030031 blocks TRPA1 without affecting TRPV1, TRPV3, TRPV4, TRPM8 
or 48 other receptors, transporters and enzymes51. A967079 has minimal activity at 89 different G-
protein-coupled receptors, enzymes, transporters, and ion channels including other TRP channels52.  
(10) TRPA1 knock-out, but not knock-out of TRPV3, slowed and greatly reduced the ischaemia-
evoked [Ca2+]i rise (Fig. 4f, g). To check for mistakes in our understanding, we applied the 
TRPA1/TRPV3 blocker IPP in the TRPA1 KO and (as expected) it had no effect, and we applied the 
TRPA1 blocker HC-030031 in the TRPV3 KO and (as expected) it greatly reduced the ischaemia-
evoked [Ca2+]i rise.  
(11) Myelin damage was reduced by the specific TRPA1 blockers HC-030031 and A967079 (Fig. 4i-
j). 
(12) The only TRP channel previously reported to be present in oligodendrocytes is TRPM3, which 
acts as a sphingosine-gated Ca2+-channel53. However, when we applied sphingosine (50 M) it evoked 
no significant increase in [Ca2+]i (R/R = 0.014+0.012, n=5, p=0.16).  
(13) The ischaemia-evoked [Ca2+]i increase was not inhibited (p>0.53, Ext. Data Fig. 6a) by agents 
blocking TRP channels other than TRPA1, as follows: flufenamic acid (250 M) which blocks27,54 
TRPP2, TRPC3, TRPC5, TRPC7, TRPM2, TRPM4 and TRPM5; ML204 (20 M) which blocks20,55 
TRPC4 and TRPC5; SKF-96365 (100 M) which blocks27,56,57 TRPV2, TRPC3, TRPC6, TRPC7 and 
TRPP1, as well as the store-operated calcium channel component STIM1 and some voltage-gated 
calcium channels; capsazepine (CPZ, 100 M) which blocks20 TRPV1 and TRPM8; FTY720 (1 M) 
which blocks58 TRPM7; RN-1734 which blocks59 TRPV4.  
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